Triple antiviral therapy in HCV positive patients who failed prior combination therapy

Table 2 Sustained virologic response for all treatment groups combined according to the baseline characteristics of patients

Characteristics	Sustained virologic response		P1
Genotype 1	32/147	22%	0.0085
Non 1	18/41	44%
Age ≤ 40 yr	13/42	31%	NS
> 40 yr	37/146	25%
BMI ≤ 25 kg/m2	32/107	30%	NS
> 25 kg/m2	12/61	20%
Stage ≤ 3	37/127	29%	NS
> 3	12/56	21%
Grade ≤ 10	42/167	25%	0.03
> 10	8/15	53%
ALT ≤ 120 UI/L	22/107	21%	0.03
> 120 UI/L	24/66	36%
HCV-RNA ≤ 2 × 106 copies/mL	23/74	31%	NS
> 2 × 106 copies/mL	7/28	25%
Previous Total IFN ≤ 500 MU	20/91	22%	NS
> 500 MU	25/82	30%

¹ Fisher's exact test; NS: Not significant.